This world-leading journal also published many outstanding clinical research articles; we suppose that targeted radiotherapy using prostate-specific membrane antigen (PSMA) radioligands in prostate cancer patients [12–17] must be a particular focus of attention for most ANM readers in Japan, who are waiting impatiently for its approval by the Japanese government. Here, FOLH1 is linked to prostate cancer.